 |
Adam Bonislawski is the editor of GenomeWeb's ProteoMonitor. He covers proteomics and life science mass spectrometry. E-mail Adam Bonislawski and follow his GenomeWeb Twitter account at @ProteoMonitor. |
BioMerieux Takes $15M Stake in Quanterix, Gains Exclusive Global License to SiMoA as IVD Platform
November 30, 2012
BioMerieux Takes $15M Stake in Quanterix, Gains Exclusive Global License to SiMoA as IVD Platform
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- BioMerieux Invests $15M in Quanterix, Will Use SiMoA to Support PSA and Infectious Disease Assays
November 27, 2012 / BioArray News - ASU's Biodesign Institute Wins $30M DoD Contract for Immunosignature-Based Pathogen Detection Chip
April 27, 2012 / ProteoMonitor - Shifting Focus From Dx Development, Quanterix Aims to Launch Commercial SiMoA Instrument in 2013
February 25, 2011 / ProteoMonitor - BioMerieux Invests $15M in Quanterix as Part of Test Development Partnership
November 15, 2012 / GenomeWeb Daily News - Quanterix Study Suggests Simoa Platform Can Compete with Nucleic Acid-Based HIV Tests
October 12, 2012 / ProteoMonitor